VKTX: Viking Therapeutics, Inc. Stock

by  •  • Comments Off on VKTX: Viking Therapeutics, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 3,124.45
Enterprise Value ($M) 3,086.51
Book Value ($M) 846.92
Book Value / Share 7.54
Price / Book 3.69
NCAV ($M) 845.95
NCAV / Share 7.53
Price / NCAV 3.69

Profitability (mra)
Return on Invested Capital (ROIC) -0.15
Return on Assets (ROA) -0.13
Return on Equity (ROE) -0.14

Liquidity (mrq)
Quick Ratio 44.25
Current Ratio 44.25

Balance Sheet (mrq) ($M)
Current Assets 866.02
Assets 866.99
Liabilities 20.07
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -150.92
Net Income -109.96
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -87.79
Cash from Investing -553.37
Cash from Financing 612.46

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
04-23 13G/A BlackRock, Inc. 4.50 -14.32
11-14 13G/A Viking Global Investors Lp 0.60 -85.97
11-12 13G/A Vanguard Group Inc 9.17 0.00
10-18 13G/A State Street Corp 4.20 -18.61

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-04-24 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2025-02-26 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One)
2024-10-23 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-07-24 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-05-08 775,068 2,837,869 27.31
2025-05-07 712,272 2,293,087 31.06
2025-05-06 1,049,553 3,472,672 30.22
2025-05-05 580,505 2,438,184 23.81

(click for more detail)

Similar Companies
UPXI – Upexi, Inc. VERU – Veru Inc.
VIVS – VivoSim Labs, Inc. VSTM – Verastem, Inc.
VTGN – Vistagen Therapeutics, Inc.


Financial data and stock pages provided by
Fintel.io